Research Analysts Issue Forecasts for NxStage Medical, Inc.’s Q2 2018 Earnings (NXTM)
NxStage Medical, Inc. (NASDAQ:NXTM) – Equities research analysts at Leerink Swann decreased their Q2 2018 earnings per share (EPS) estimates for NxStage Medical in a research report issued to clients and investors on Wednesday. Leerink Swann analyst D. Antalffy now forecasts that the medical device company will earn $0.01 per share for the quarter, down from their prior forecast of $0.04. Leerink Swann currently has a “Market Perform” rating and a $30.00 target price on the stock. Leerink Swann also issued estimates for NxStage Medical’s Q3 2018 earnings at $0.05 EPS, FY2018 earnings at $0.13 EPS, FY2019 earnings at $0.48 EPS and FY2020 earnings at $0.76 EPS.
Several other equities research analysts have also recently commented on NXTM. BTIG Research reaffirmed a “buy” rating and set a $27.00 price objective on shares of NxStage Medical in a research report on Wednesday, May 10th. Jefferies Group LLC dropped their price objective on NxStage Medical from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, May 10th. Craig Hallum started coverage on NxStage Medical in a research report on Tuesday, June 27th. They set a “buy” rating and a $32.00 price objective on the stock. BidaskClub raised NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday, June 30th. Finally, Northland Securities reaffirmed a “hold” rating and set a $30.00 price objective on shares of NxStage Medical in a research report on Monday, August 7th. One analyst has rated the stock with a sell rating and nine have issued a hold rating to the company. The stock has an average rating of “Hold” and an average target price of $30.25.
COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/07/research-analysts-issue-forecasts-for-nxstage-medical-inc-s-q2-2018-earnings-nxtm.html.
Shares of NxStage Medical (NXTM) traded up 0.22% during midday trading on Thursday, reaching $27.89. The company’s stock had a trading volume of 108,317 shares. The company’s market capitalization is $1.84 billion. NxStage Medical has a 1-year low of $20.45 and a 1-year high of $30.80. The stock has a 50 day moving average of $26.82 and a 200-day moving average of $25.93.
NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.03). NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The company had revenue of $92.20 million for the quarter, compared to analyst estimates of $96.47 million. During the same quarter in the previous year, the company earned ($0.03) EPS. The firm’s revenue for the quarter was up .0% compared to the same quarter last year.
A number of hedge funds have recently bought and sold shares of NXTM. BlackRock Inc. lifted its holdings in NxStage Medical by 38,360.4% in the first quarter. BlackRock Inc. now owns 4,413,326 shares of the medical device company’s stock valued at $118,408,000 after acquiring an additional 4,401,851 shares during the period. FMR LLC lifted its holdings in NxStage Medical by 31.8% in the second quarter. FMR LLC now owns 9,860,278 shares of the medical device company’s stock valued at $247,197,000 after acquiring an additional 2,378,077 shares during the period. Eagle Asset Management Inc. bought a new position in NxStage Medical in the first quarter valued at about $54,558,000. William Blair Investment Management LLC lifted its holdings in NxStage Medical by 491.6% in the second quarter. William Blair Investment Management LLC now owns 1,959,318 shares of the medical device company’s stock valued at $49,120,000 after acquiring an additional 1,628,114 shares during the period. Finally, Redmile Group LLC bought a new position in NxStage Medical in the second quarter valued at about $16,480,000. 93.20% of the stock is currently owned by institutional investors.
In other NxStage Medical news, President Joseph E. Turk, Jr. sold 24,000 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $29.64, for a total value of $711,360.00. Following the transaction, the president now owns 82,903 shares of the company’s stock, valued at $2,457,244.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Matthew W. Towse sold 4,300 shares of the stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $23.29, for a total value of $100,147.00. Following the completion of the transaction, the senior vice president now directly owns 29,637 shares in the company, valued at approximately $690,245.73. The disclosure for this sale can be found here. In the last three months, insiders sold 54,900 shares of company stock worth $1,491,266. 4.70% of the stock is owned by corporate insiders.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.